AKT1 and lung cancer: A study by Mei-ying et al., 2019 showed that Naringin increased the uptake of cisplatin and decreased its efflux and sensitivity to cisplatin in lung-cancer resistant strain A549/DDP cells by upregulating Bax expression and downregulating P-gp, MRP1, p-Akt, and chemokine receptor CXCR4 protein levels.